Methotrexaat Nordic

Methotrexate, the active ingredient in Methotrexaat Nordic, is an antimetabolite presented as a subcutaneous injection for subcutaneous use. It works by inhibiting dihydrofolate reductase, thereby reducing DNA synthesis and cell replication. The drug is indicated for managing autoimmune conditions such as rheumatoid arthritis and psoriasis, as well as for treating certain hematologic malignancies in both adult and pediatric patients.

GNH USA supplies Methotrexaat Nordic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this essential immunosuppressant for qualified healthcare providers.

Methotrexate is used across several disease pathways, primarily targeting immune‑mediated inflammation and malignant cell proliferation.

- Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage progression. - Psoriasis: decreases skin lesion severity and plaque formation. - Acute lymphoblastic leukemia: impedes leukemic cell growth and improves remission rates. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination chemotherapy regimens.

Methotrexate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Mouth sores (stomatitis) - Elevated liver enzymes - Diarrhea - Hair thinning

Serious or Rare Side Effects: - Severe infection due to bone marrow suppression - Pulmonary toxicity (interstitial pneumonitis) - Hepatic fibrosis or cirrhosis with long‑term use - Aplastic anemia - Severe skin reactions (Stevens‑Johnson syndrome)

When prescribing methotrexate, clinicians should observe several precautionary measures to minimize toxicity.

- Monitor liver function: perform baseline and periodic liver enzyme tests. - Monitor blood counts: check complete blood count regularly for cytopenias. - Assess renal function: adjust dose in patients with impaired clearance. - Avoid use in pregnancy: contraindicated due to teratogenic risk. - Review concomitant NSAID or sulfonamide use: may increase toxicity. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase risk of renal toxicity and gastrointestinal ulceration. - Penicillins (e.g., amoxicillin): may reduce methotrexate clearance, raising serum levels. - Sulfonamides (e.g., trimethoprim‑sulfamethoxazole): potentiate bone marrow suppression.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Live vaccines: immunosuppression can diminish vaccine efficacy and increase infection risk.